•  
  • Home > About Us

    About Us

  • About Naurex

    Leadership

  • Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the NMDA receptor (NMDAR).

    Existing NMDAR Agents: Clinically Validated Efficacy But Serious Safety Issues

    Existing NMDAR antagonists, such as ketamine, have garnered significant attention for their remarkalbe efficacy in patients with severe and treatment-resistant depression. However, ketamine and drugs like it have psychosis-like side effects and are also drugs of abuse, limiting their therapeutic potential.

    The Naurex Breakthrough: Novel, Safe and Effective NMDAR Modulators

    Naurex researchers have generated novel chemical drug classes and a platform for discovering molecules that are partial agonists of the NMDA receptor. These partial agonists modulate the NMDA receptor in a different way than existing agents, exhibiting the remarkable efficacy potential of drugs such as ketamine, but without their limitng side effects. Naurex’s drug development programs include compounds with high potential for the treatment of mood and anxiety disorders, cognitive disorders, developmental disorders, neurodegeneration, neuropathic pain and addiction.

    Naurex's 1st-generation compound, GLYX-13, is a partial agonist of the NMDA receptor currently in Phase II clinical development as a therapy for patients who don't respond well to current antidepressants. In preclinical studies, it exhibited promising ketamine-like efficacy signatures, but without ketamine’s limiting side effects. Its strong safety profile and efficacy potential have been confirmed in Phase I and Phase II clinical trials.

    Naurex intends to file an IND for its 2nd-generation compound, NRX-1074, in early 2013. NRX-1074 is an orally bioavailable molecule that will be developed as a therapy for major depressive disorder. It is a partial agonist of the NMDA receptor, is based on the same platform as GLYX-13, and in preclinical studies has shown similar promising ketamine-like efficacy signatures without apparent safety issues.

    The company is also advancing 3rd-generation molecules based on its NMDAR modulation platform with varied activity and selectivity profiles that have high potential in a number of CNS disorders.